

3. 米国の動向

米国でもナノテクノロジーやナノマテリアルの安全性に対する議論の必要性は早くから認識されているが、欧州のような包括的な法的規制にまでには至っていない。化学物質管理の観点からは、2007年にU. S. Environmental Protection Agency (EPA) が有害物質管理法 (Toxic Substances Control Act; TSCA) の下に、ナノマテリアルを取り扱う企業等に対し自主的なデータの提出を促すスチュワードシッププログラムを開始したが、期待したほどの情報を得られないようであった。しかしEPAは2010年から、単層多層のカーボンナノチューブについて、製品毎の製造前届出 (PMN) を必要とする重要新規利用ルール (significant new use rule; SNUR) を公布した。⁵⁾ 届けデータとしては、懸念されている吸入曝露影響に対して90日間吸入試験等が要求されており、実質的に必要な試験項目として認識されつつある。しかし、この製造前届出データの範囲は各製品に対応したケースバイケースの措置の結果であり、さらに化学的特性等は企業秘密として開示されていないことも含め一般化される評価指針として利用することはできない。

一方U. S. Food and Drug Administration (FDA) は、2007年に公表されたナノテクノロジータスクフォースの報告書を受けて、2011年6月によく業界向けに「FDA規制権限製品にナノテクノロジーが利用されているかどうかの検討」に関するガイダンス案を公表した。⁶⁾ このガイダンスでは、ナノマテリアルの定義としてそれまでに通常使用されてきた「三次元のうち少なくとも一次元のサイズが1から100 nmの範囲に入る」という定義に加えて、たとえば100 nmを超えるサイズであったとしても、そのサイズに起因した物理学的あるいは生物学的特性を示すかどうかという点にも着目している。その際の検討するサイズの上限を1 μm としている。その後、具体的なFDA規制関連製品に関するガイダンスとして、2012年4月に食品材料及び食品接触物質 (食器など)⁷⁾ と、化粧品⁸⁾ の安全性評価に関する業界向けのガイダンスをそれぞれ公表した。化粧品は、着色料を除いては事前承認が必要ではないが、安全性確保のための製造業者等の責任において、考慮すべき安全性評価上の論点が示されており、以下に示す因子が重要であるとされている。

- 物理化学的特性
- 最終製品に対応した毒性試験条件での凝集状態と粒径分布
- 不純物
- 製品からの曝露可能レベルと最終製品中での凝集性
- *in vitro* 及び *in vivo* 試験に供する用量の測定法
- 化粧品成分とそれらの不純物に関する *in vitro* と *in vivo* の毒性データ、皮膚透過性、眼及び皮膚刺激性、感作性、変異原性/遺伝毒性
- 化粧品成分や最終製品に対するヒトボランティア臨床試験

また、化粧品の安全性試験としてナノマテリアルの評価に適した *in vitro* 試験開発の重要性にも触れているが、試験系における凝集性について対応することが必要であるとされている。特に不溶性のナノ粒子については *in vivo* 試験の方が適切であるかもしれないとコメントしている。

食品材料及び食品接触物質のガイダンスにおいては、既認可食品及び食品接触成分に対してナノテクノロジーを利用して製造工程を変更した場合に対して、安全性評価上検討すべき論点について記されている。重要な製造工程の変更としては、出発物質の種類や濃度変更、及び触媒の変更と並んで食品成分の粒子サイズに影響を与えるような新技術が例示として挙げられている。勧告案は、21CFR (連邦規則集) に記載された食品添加物及び色素、21CFRの *generally recognized as safe* (GRAS) として同定された物質、*food contact notification* (FCN) 申請された食品接触物質、既にGRASとしての使用が、認証された物質の4分類に分けて記載されている。しかし、各々の物質に対して検証すべき項目はほぼ同様で、既に認証あるいは申請が認められた成分との同一性に影響を及ぼした物理化学的特性と、その変化に対応した安全性評価を行うこと、製造過程の変更の度合いやその結果製造された製品の規格や不純物が法的基準の範囲に入るかどうかを検証することといったような、抽象的な記載となっている。さらに最終的には、必要に応じてFDAと相談することが推奨されている。

4. 国際機関の動向

化学物質管理関係では、欧米におけるナノマテリ

アルの安全性に関する議論が本格化し始めた 2006 年に OECD では Chemical Committee (化学委員会) の下に Working Party on Manufactured Nanomaterials (WPMN; 工業ナノ材料に関する作業部会) が設置され、以下に示す 9 つの steering group (SG) によって検討が進められている。

- SG1: Development of a Database on Human Health and Environmental Safety Research;
- SG2: Research Strategies on Manufactured Nanomaterials;
- SG3: Safety Testing of a Representative Set of Manufactured Nanomaterials;
- SG4: Manufactured Nanomaterials and Test Guidelines;
- SG5: Co-operation on Voluntary Schemes and Regulatory Programmes;
- SG6: Co-operation on Risk Assessment;
- SG7: The Role of Alternative Methods in Nanotoxicology;
- SG8: Exposure Measurement and Exposure Mitigation;
- SG9: Environmentally Sustainable Use of Man-

ufactured Nanomaterials

SG3-SG8 では、リスク評価に直接あるいは間接に係わる活動であるが、このうち SG4 では各種試験法のガイドラインをナノマテリアルに適合させるために最も重要なファクターである、試験サンプルの調整法や用量設定に関して考慮すべき論点について、各種試験法毎に取りまとめて公表している。⁹⁾ また、SG3 においては、実際に代表的なナノマテリアルに関して加盟国が自主的に物性情報や安全性データを収集、場合によっては毒性試験を行うというスポンサーシッププログラムが最も精力的に活動している (Table 1)。日本は米国とともに、フラーレンや単層及び多層カーボンナノチューブの 3 種類のナノマテリアルのスポンサー国となっている。¹⁰⁾ 2012 年時点では、対象となっている 13 種のナノマテリアルの半数近くの物質について、物性データや初期的な毒性試験データが出揃う予定となっている。今後は毒性情報等を取りまとめた Dossier 文書等の作成が行われ、OECD において高生産量化学物質に対して経常的に行われている化学物質共同評価プログラム (cooperative chemical assessment program; CoCAM) 等を介して、初期的な健康及び環境影響評価が行われることが想定されている。

Table 1. Sponsorship Arrangements at the WPMN Sponsorship Program

Manufactured Nanomaterial	Lead sponsor (s)	Co-sponsor (s)	Contributors
Fullerenes (C60)	Japan, US		Denmark, China
SWCNTs	Japan, US		Canada, France, Germany, EC, China, BIAC
MWCNTs	Japan, US	Korea, BIAC	Canada, France, Germany, EC, China, BIAC
Silver nanoparticles	Korea US	Australia, Canada, Germany, Nordic Council of Ministers	France, Netherlands, EC, China, BIAC
Iron nanoparticles	China	BIAC	Canada, US, Nordic Council of Ministers
Titanium dioxide	France Germany	Austria, Canada, Korea, Spain, US, EC, BIAC	Denmark, Japan, United Kingdom, China
Aluminium oxide			Germany, Japan, US
Cerium oxide	US UK/BIAC	Australia, Netherlands, Spain	Denmark, Germany, Japan, Switzerland, EC
Zinc oxide	UK/BIAC	Australia, US, BIAC	Canada, Denmark, Germany, Japan, Netherlands, Spain, EC
Silicon dioxide	France, EC	Belgium, Korea, BIAC	Denmark, Japan
Dendrimers		Spain, US	Austria, Korea
Nanoclays	BIAC		Denmark, US, EC
Gold nanoparticles	South Africa	US	Korea, EC

食品関係では、2009年にFAOとWHOの専門家による合同会議が企画され、食品及び農業分野へのナノテクノロジーの適用に関する食品の安全性への意義付けについてのレポートが公表された。¹¹⁾ 这其中では、食品・飼料へのナノテクノロジーの利用に対する段階的リスクアセスメントアプローチの利用に関して、より科学的な勧告を模索することを検討すべきであることが提言されている。また、有効性が確認されるべき試験法やガイダンスの開発には、以下の分野におけるデータギャップが今後明らかにされるべきであるとしている。

- 食品・飼料中のナノマテリアルの物理化学的特性を適切に解析する手法
- 食品、試料、農産物の基質中に存在するナノマテリアルの特性
- 生体試料中に存在するナノ粒子の確認法
- *in vitro*, *in vivo*, *ex vivo* and *in silico* 試験法
- ナノマテリアルの体内動態、特に生物学的バリアー(粘膜、脳血液関門、血液胎盤関門など)を通過することによる未知の体内分布や作用メカニズム
- 実際の使用用量におけるナノマテリアルの特性

一方、化粧品分野では日本(厚生労働省)、米国(FDA)、カナダ(厚生省)、EC(企業産業総局)の間で国際協力と情報交換を行う場である化粧品規制協力国際会議(International Cooperation on Cosmetics Regulation; ICCR)において、2010年には化粧品中のナノマテリアルの基準や検出法について取りまとめた報告書が公表された。その後、2011年より安全性評価手法を検討する作業グループが組織され、現在、評価ガイダンスの作成が進行中である。

5. おわりに

本稿では有害性評価の観点からガイダンスの作成状況を取りまとめたため、特にとりあげなかったが、2011年の10月には欧州委員会(European Commission; EC)は規制上のナノマテリアルを「個数濃度のサイズ分布で50%以上の粒子について1つ以上の外径が1 nm から 100 nm のサイズ範囲である粒子」と定義した。¹²⁾ この場合のサイズ分布の閾値である「50%」は規制上の値であり、有害性評価の観点からの科学的な値ではない。2014年12月ま

でこの数字は見直すことになっているが、申請側の産業界としては大きな問題である。一方で米国FDAは、1 nm から 100 nm のサイズ範囲にもとらわれることなく、その物性や生態影響に与える大きさにより、ケースバイケースの対応をとるという姿勢から、明確な定義を規定していない。これは両地域での許認可行政の運用システムの違いが、部分的に影響していると思われる。米国では基本的に商品としての製品ベースで許認可を行うケースが多く、安全性評価についても各企業等と個別に対応する体制を取り易いことによるものと考えられる。米国におけるこのような個別申請で対応するという傾向は、食品添加物や化粧品のようにナノマテリアルの使用用途が厳密に規定されていないような、工業用製品の原料となるナノマテリアルの製造に係わる化学物質管理体制においても認められる。

つまりナノマテリアルのリスクは、その使用用途によっても異なってくるため、様々な用途に適用可能なように開発された原料であるナノマテリアルの安全性を包括的に評価しようとするならば、多方面での用途を想定した概略的な評価ガイダンスしかできない。しかしながら、用途をある程度限定するならば、より具体的な評価ガイダンスを作成できると考えることができる。このことは、化学物質管理システムとして、物質ベースでナノマテリアルを評価するための枠組みを構築している活動よりも、食品添加物や食器、化粧品などといったように用途を規定した中でのナノマテリアルの評価ガイダンスが先行して公表されている現状と一致しているものと考えられる。しかし各国、地域が各々のシステムの中で独自に評価するという状態は、グローバル化しているナノマテリアル産業界にとって好ましいものではない。今後は、各用途分野に対する評価ガイダンスであっても国際的なハーモナイゼーションや、評価事例情報の共有化を進めることにより、より効率的で国際的なナノマテリアルの健康影響評価体制の構築が望まれる。

謝辞 本稿での解説の基となった情報の一部は、厚生労働科学研究費補助金(化学物質リスク研究事業) H21-化学-一般-008 及び H24-化学-指定-009 の助成によって行われた。

REFERENCES

- 1) Hankin S. M., Peters S. A. K., Poland C. A., Foss Hansen S., Holmqvist J., Ross B. L., Varet J., Aitken R. J., "Specific Advice on Fulfilling Information Requirements for Nanomaterials under REACH (RIP-oN 2)-Final Project Report," RNC/RIP-oN2/FPR/1/FINAL, 2011.
- 2) European Food Safety Authority (EFSA) Scientific Committee, *The EFSA Journal*, **958**, 1-39 (2009).
- 3) European Food Safety Authority (EFSA) Scientific Committee, *EFSA Journal*, **9(5)**, 2140 (2011).
- 4) Scientific Committee on Consumer Safety (SCCS), "Guidance on the Safety Assessment of Nanomaterials in Cosmetics," SCCS/1484/12, 2009.: (http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_s_005.pdf), cited August 20, 2012.
- 5) U. S. Environmental Protection Agency (EPA), *Fed. Regist.*, **75(180)**, 56880-56889 (2010).
- 6) U. S. Food and Drug Administration (FDA), "Draft Guidance for Industry; Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology," 2011.: (<http://www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm>), cited August 20, 2012.
- 7) U. S. Food and Drug Administration (FDA), "Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that are Color Additives; Draft Guidance," 2012.: (<http://www.fda.gov/downloads/Cosmetics/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/UCM300927.pdf>), cited August 20, 2012.
- 8) U. S. Food and Drug Administration (FDA), "Guidance for Industry: Safety of Nanomaterials in Cosmetic Products, Draft Guidance," 2012.: (<http://www.fda.gov/downloads/Cosmetics/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/UCM300932.pdf>), cited August 20, 2012.
- 9) Organization for Economic Co-operation and Development (OECD), Environment Directorate, "Preliminary Guidance Notes on Sample Preparation and Dosimetry for the Safety Testing of Manufactured Nanomaterials," ENV/JM/MONO(2010)25, OECD, Paris, 2010.
- 10) Organization for Economic Co-operation and Development (OECD), Environment Directorate, "Guidance Manual for the Testing of Manufactured Nanomaterials: OECD's Sponsorship Programme; First Revision," ENV/JM/MONO(2009)20/REV, OECD, Paris, 2010.
- 11) Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO), "FAO/WHO, Expert Meeting on the Application of Nanotechnologies in the Food and Agriculture Sectors: Potential Food Safety Implications, Meeting Report," 2010.: (<http://www.fao.org/docrep/012/i1434e/i1434e00.pdf>), cited August 20, 2012.
- 12) European Commission. *Official Journal of the European Union*, L 275, 20.10.2011, 38-40 (2011).

Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles

Jiegou Xu · Mitsuru Futakuchi · David B. Alexander · Katsumi Fukamachi · Takamasa Numano · Masumi Suzui · Hideo Shimizu · Toyonori Omori · Jun Kanno · Akihiko Hirose · Hiroyuki Tsuda

Received: 25 February 2013 / Accepted: 20 June 2013 / Published online: 6 July 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract Zinc oxide (ZnO) is known to induce lung toxicity, including terminal bronchiolar epithelial hyperplasia, which gives rise to concerns that nanosized ZnO (nZnO) might lead to lung carcinogenesis. We studied the tumor promoting activity of nZnO by an initiation–promotion protocol using human *c-Ha-ras* proto-oncogene transgenic rats (*Hras*128 rats). The rats were given 0.2 % N-nitrosobis(2-hydroxypropyl)amine (DHPN) in the drinking water for 2 weeks and then treated with 0.5 ml of 250 or 500 µg/ml nZnO suspension by intra-pulmonary spraying once every 2 weeks for a total of 7 times. Treatment

with nZnO particles did not promote DHPN-induced lung carcinogenesis. However, nZnO dose-dependently caused epithelial hyperplasia of terminal bronchioles (EHTB) and fibrosis-associated interstitial pneumonitis (FAIP) that were independent of DHPN treatment. Tracing the fate of EHTB lesions in wild-type rats indicated that the hyperplastic lesions almost completely disappeared within 12 weeks after the last nZnO treatment. Since nZnO particles were not found in the lung and ZnCl₂ solution induced similar lung lesions and gene expression profiles, the observed lesions were most likely caused by dissolved Zn²⁺. In summary, nZnO did not promote carcinogenesis in the lung and induced EHTB and FAIP lesions that regressed rapidly, probably due to clearance of surplus Zn²⁺ from the lung.

Electronic supplementary material The online version of this article (doi:10.1007/s00204-013-1086-5) contains supplementary material, which is available to authorized users.

J. Xu · D. B. Alexander · H. Tsuda (✉)
Laboratory of Nanotoxicology Project, Nagoya City University,
3-1 Tanabedohri Mizuho-ku, Nagoya 467-8603, Japan
e-mail: htsuda@phar.nagoya-cu.ac.jp

J. Xu · M. Futakuchi · K. Fukamachi · T. Numano · M. Suzui
Department of Molecular Toxicology, Nagoya City University
Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho,
Mizuho-ku, Nagoya 467-8601, Japan

H. Shimizu
Core Laboratory, Nagoya City University Graduate School
of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku,
Nagoya 467-8601, Japan

T. Omori
Department of Health Care Policy and Management, Nagoya City
University Graduate School of Medical Sciences, 1-Kawasumi,
Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan

J. Kanno · A. Hirose
National Institute of Health Sciences, 1-18-1 Kamiyoga,
Setagaya-ku, Tokyo 158-8501, Japan

Keywords Nanosized zinc oxide particles · Lung toxicity · Lung carcinogenesis · Epithelial hyperplasia of terminal bronchioles · Interstitial pneumonitis · Lung fibrosis

Introduction

One of the most widely used nanomaterials is nZnO. The worldwide production of nZnO powder is increasing every year and was reported to have reached 1.4 million tons in 2011. It is used in rubber industry and electronics and in commercial products such as sunscreens and paints. In the biomedical field, it is used in baby powders, antiseptic ointments, and zinc oxide tapes to treat a variety of skin conditions (Baldwin et al. 2001; Hughes and McLean 1988). Recently, nZnO has gained interest in cancer applications or as an active anticancer drug (Rasmussen et al. 2010).

Micron or larger-sized ZnO particles are considered to be “Generally Recognized as Safe” (GRAS) in food

additives by the FDA. However, exposure to fumes containing ZnO and other metal particles during welding or galvanizing processes is known to lead to metal fume fever (Antonini et al. 2003; Drinker and Fairhall 1933; Fine et al. 1997). Recent reports have shown that nZnO affects cell viability and induces reactive oxygen species (ROS) in many mammary cell types in tissue culture (Deng et al. 2009; Lee et al. 2008; Xia et al. 2008; Yang et al. 2009), cause proliferation of airway epithelial cells, goblet cell hyperplasia, interstitial pulmonary inflammation and fibrosis (Cho et al. 2011), and reversible inflammatory reaction in the bronchoalveolar lavage fluid in animal studies (Sayes et al. 2007; Warheit et al. 2009). nZnO also leads to DNA damage (Kermanizadeh et al. 2012) and micronuclei formation in vitro (Valdiglesias et al. 2013). While these in vitro and in vivo studies have provided some information on acute toxic effects of nZnO on certain cell types and animals, further in vivo studies are needed to determine whether nZnO has chronic toxic effects as in some other metal oxide particles. For example, epidemiological data indicate that exposures of aluminum oxide or iron oxide lead to pneumoconiosis in human (Hull and Abraham 2002; Sano 1963); titanium dioxide has carcinogenic activity in the rat lung (Heinrich et al. 1995; Xu et al. 2010). Such chronic toxicity data will have more impact on risk assessment of nZnO.

Since nZnO induces inflammatory reaction, ROS production, and genotoxicity, which are implicated in cancer development, in the present study, we tested the lung carcinogenicity of nZnO by an initiation–promotion protocol using human *c-Ha-ras* proto-oncogene transgenic (*Hras* 128) rats, which have the same susceptibility to chemically induced lung carcinogenesis as their parent wild-type rats, but are highly susceptible to mammary tumor induction (Tsuda et al. 2005). The results indicated that nZnO did not have promotion effect on DHPN-induced lung and mammary carcinogenesis and caused reversible EHTB and FAIP.

Materials and methods

Animals

Forty-three female transgenic rats carrying the human *c-Ha-RAS* proto-oncogene (*Hras*128 rats) and 42 female wild-type Sprague–Dawley rats were obtained from CLEA Japan Co., Ltd. (Tokyo, Japan). The animals were housed in the Animal Center of Nagoya City University Medical School and maintained on a 12-h light/12-h dark cycle and received Oriental MF basal diet (Oriental Yeast Co. Ltd., Tokyo, Japan) and water ad libitum. The study was conducted according to the Guidelines for the Care and Use

of Laboratory Animals of Nagoya City University Medical School, and the experimental protocol was approved by the Institutional Animal Care and Use Committee (H22M-19).

Preparation, characterization of nZnO suspensions, and administration of nZnO to the lung

Zinc oxide particles (CAS No. 1314-13-2, MZ-500, without coating, with a mean primary diameter of 25 nm) were obtained from Tayca Cooperation, Osaka, Japan. The particles were suspended in 0.1 % Tween 20 saline at 250 or 500 $\mu\text{g/ml}$. The suspension was sonicated for 20 min to prevent aggregate formation.

Characterization of nZnO was conducted as follows: the shape of nZnO in the suspensions was imaged by transmission electron microscopy (TEM); element analysis was performed by an X-ray microanalyzer (EDAX, Tokyo, Japan), after aliquots of nZnO were loaded on a carbon sheet; the size distribution of nZnO in the 500 $\mu\text{g/ml}$ suspension was analyzed using a Particle Size Distribution Analyzer (Shimadzu Techno-Research, Inc., Kyoto, Japan). The characterization results are shown in Figure S1.

Before being administrated to rats, the nZnO suspensions were further sonicated for 20 min. 0.5 ml of the nZnO suspensions was administrated to the lung by intra-pulmonary spraying (IPS) as described previously (Xu et al. 2010).

Carcinogenicity study

The carcinogenic activity of nZnO was assessed in female *Hras*128 rats using an initiation–promotion protocol by which we used previously to evaluate lung and mammary carcinogenicity of titanium dioxide nanoparticles (Xu et al. 2010). Briefly, three groups of 10–11 female *Hras*128 rats aged 6 weeks were given 0.2 % DHPN (Wako Chemicals, Co., Ltd. Osaka, Japan) in the drinking water for 2 weeks, and Groups 4 and 5 (6 rats each) were given drinking water without DHPN. Two weeks later, Group 1 and Group 4 were administered 0.1 % Tween 20 saline, and Group 2, Group 3, and Group 5 were administered 250, 500, and 500 $\mu\text{g/ml}$ nZnO suspensions by IPS once every two weeks from the end of week 4 to week 16, a total of 7 times. The total amounts of nZnO administered to Groups 1, 2, 3, 4, and 5 were 0, 0.875, 1.75, 0, and 1.75 mg/rat, respectively. The dosing was determined according to the permissible exposure limit for zinc oxide particles of the Occupational Safety and Health Administration (OSHA) (see Discussion). Three days after the last treatment, animals were killed and the organs (brain, lung, liver, spleen, kidney, mammary gland, ovaries, uterus, and neck lymph nodes) were fixed in 4 % paraformaldehyde in PBS buffer adjusted to pH 7.3 and processed for histological examination and transmission electron microscopy (TEM).

Light microscopy, polarized light microscopy, and transmission electron microscopy

Hematoxylin–Eosin (H&E)-stained pathological slides of the lung and other major organs were used to observe nZnO with a light microscope and polarized light microscope (PLM) (Olympus BX51N-31P-O polarized light microscope, Tokyo, Japan) at 1,000× magnification. Localization of the illuminated particles was confirmed in the same H&E-stained sections after removing the polarizing filter.

Paraffin blocks were deparaffinized and embedded in epon resin and processed for nZnO observation and zinc element analysis, using a JEM-1010 transmission electron microscope (TEM) (JEOL, Co. Ltd, Tokyo, Japan) equipped with an X-ray microanalyzer (EDAX, Tokyo, Japan).

Immunohistochemistry and Azan–Mallory staining

PCNA was detected using an anti-PCNA monoclonal antibody (Clone PC10, Dako Japan Inc., Tokyo, Japan). The antibody was diluted 1:200 in blocking solution and applied to deparaffinized slides, and the slides were incubated at 4 °C overnight. The slides were then incubated for 1 h with biotinylated species-specific secondary antibodies diluted 1:500 (Vector Laboratories, Burlingame, CA) and visualized using avidin-conjugated horseradish peroxidase complex (ABC kit, Vector Laboratories). To assess lung fibrosis, paraffin-embedded slides were deparaffinized, and collagen fibers were visualized by Azan–Mallory staining.

Reversibility study and effects of ZnCl₂ solution

To assess whether nZnO-induced terminal bronchiolar epithelial hyperplasia, interstitial pneumonitis, and lung fibrosis are reversible, we conducted reversibility experiments. Seven groups of 5 female wild-type Sprague–Dawley rats aged 10 weeks were administered 0.5 ml of 0.1 % Tween 20 saline or 500 µg/ml nZnO suspension by IPS 2 times per week for 4 weeks. Group 1 was treated with 0.1 % Tween 20 saline and killed 1 day after the last IPS. Groups 2–7 were treated with 0.5 ml of 500 µg/ml nZnO suspension and killed at 1 day and 2, 4, 6, 8, and 12 weeks after the last IPS. For the comparison of the effects of zinc ion and nZnO, Group 8 was treated with 0.5 ml of 6.17 mM ZnCl₂ solution (the molecular amount is equal to that of 500 µg/ml nZnO suspension) by IPS at the same frequency and time period as the nZnO groups and killed 1 day after the last IPS. The left lung was cut into pieces and frozen in liquid nitrogen for biochemical analysis, and the right lung was processed for histological examination. Other major organs were excised for histological examination, and the blood was collected for cytological and biochemical analysis.

Gene expression analysis

The left lungs from Groups 1, 2, and 8 in the reversibility study described above were used for isolation of RNA. RNA was isolated by using TRizol reagent (Invitrogen of Life Technologies, CA).

For microarray analysis, 1 µg RNA from each rat of Group 1 was combined and 1 µg RNA from each rat of Group 2 was combined. The quality of the 2 mixtures of RNA samples was assessed and quantified using the Agilent 2100 BioAnalyzer RNA Nano chip system (Agilent Technologies, CA) prior to further manipulation. Microarray analysis was conducted by the 3-D Gene Chip (Toray Industries Inc., Kanagawa, Japan), and a total of 20,000 genes were analyzed. Microarray-based pathway analysis was performed by Toray Industries Inc., Kanagawa, Japan.

For reverse transcription-PCR (RT-PCR) and real-time PCR, first-strand cDNA synthesis from 1 µg of RNA was performed using SuperScript™ III First-Strand Synthesis System (Invitrogen of Life Technologies, CA) according to the manufacturer's instructions. Primers are as follows: forward primer, 5'-TAGAATCGAGGTGCACAGGAGT-3', reverse primer, 5'-TATCCAGCAGGCTGTCAAAGA-3', product size, 228 bp for Orm1; forward primer, 5'-AAGTG-GAGGAGCAGCTGGAGTGG-3', reverse primer, 5'-CCA AAGTAGACCTGCCCGACTC-3', product size, 155 bp for Tnfa, and forward primer, 5'-AGCCATGTACGTAG CCATCC-3', reverse primer, 5'-CTCTCAGCTGTGGTGG TGAA-3', product size, 228 bp for Actb. RT-PCR was conducted using an iCycler (BioRad Life Sciences, CA) as follows: 95 °C 20 s, 60 °C 20 s, 72 °C 30 s, 30 cycles for Orm1; 95 °C 20 s, 60 °C 20 s, 72 °C 20 s, 25 cycles for Tnfa, and 95 °C 20 s, 60 °C 20 s, 72 °C 30 s, 15 cycles for Actb. Real-time PCR analysis of Orm1 and Tnfa gene expression was performed with the 7300 real-time PCR system (Applied Biosystem, CA) using the premix reagent Power SYBR Green PCR Master Mix (Applied Biosystem, CA) according to the manufacturer's instructions. The Actb gene was used as the normalizing reference gene.

Determination of zinc ion

For detection of Zn²⁺ content in the lung tissue, 50–100 mg of the frozen lung tissues from the reversibility study described above were thawed at room temperature, rinsed with cold PBS 3 times, and homogenized for 30 s at the highest speed in 1 ml of T-PER, tissue protein extraction reagent (Pierce, Rockford, IL), with Polytron R PT 2100 homogenizer (Capitol Scientific Inc., TX). The homogenates were clarified by centrifugation at 10,000×g for 15 min at 4 °C, and the supernatants were used for Zn²⁺

detection. Zn^{2+} detection was performed using Quanti-Chrom™ Zinc Assay kit (BioAssay Systems, CA) according to the manufacturer's instructions.

In vitro nZnO dissolution assay

5 μ l of 500 μ g/ml nZnO suspension (2.5 μ g/tube) and increasing amounts of 1 mg/ml human α 1 acid glycoprotein (Sigma-Aldrich, product number G9885) or bovine serum albumin (Sigma-Aldrich, product number A2058) were added to microtubes, and the total volume of each tube was adjusted to 100 μ l with 0.1 % Tween 20 saline. The final protein concentration of human α 1 acid glycoprotein or bovine serum albumin was 0, 100, 200, 300, 400, and 500 μ g/ml. The tubes were then incubated at 37 °C for 2 h. The nZnO particles were removed by centrifugation at 10,000 \times *g* for 5 min, and Zn^{2+} concentration in the supernatants was determined as described above.

In vitro cytotoxicity assay

The induction and preparation of rat primary alveolar macrophages (PAM) has been described (Xu et al. 2010). 5×10^3 PAMs, 1×10^3 A549 cells (human lung adenocarcinoma cell line), and 2×10^3 CCD34 cells (human lung fibroblast cell line) were seeded into 96-well culture plates and cultured overnight in 100 ml of RPMI 1,640 containing 10 % FBS. The cells were added with nZnO suspension or ZnCl₂ solution to final concentrations of 0, 1, 5, or 25 μ g/ml of nZnO and 0, 12.3, 61.7, or 308.6 nM of ZnCl₂ (1, 5, and 25 μ g/ml of nZnO are equal to 12.3, 61.7, and 308.6 nM of ZnCl₂, respectively, in the amount of zinc element) and incubated for another 72 h. The cell viability was then determined using the Cell Counting Kit-8 (Dojindo Molecular Technologies, Rockville, MD) according to the manufacturer's instruction.

Statistical analysis

Statistical analysis was performed using ANOVA. Statistical significance was analyzed using a two-tailed Student's *t*-test. A *p* value of <0.05 was considered to be significant.

Results

Carcinogenesis study in *Hras*128 rats

DHPN-induced lung alveolar cell hyperplasia and adenoma development was used for the end point observation to assess the carcinogenicity of nZnO in our medium-term assay. As shown in Table 1, the incidence and multiplicity (number/cm² lung tissue section) of

Table 1 Effect of nZnO on lung proliferative lesions in H128-rats rats

Treatment	No. of rats	DHPN-induced proliferative lesions				DHPN-independent EHTB ^a		
		ACH ^a		Ade ^a		ACH + Ade		
		Inc. ^a (%)	Multiplicity ^b (no./cm ² lung)	Inc. (%)	Multiplicity ^b (no./cm ² lung)	Inc. (%)	Multiplicity ^b (no./cm ² lung)	
DHPN + vehicle	11	11 (100)	2.43 ± 1.29	2 (18.1)	0.09 ± 0.20	11 (100)	2.52 ± 1.26	0
DHPN + 250 μ g/ml nZnO	10	10 (100)	1.64 ± 1.09	3 (30.0)	0.12 ± 0.19	10 (100)	1.76 ± 1.03	7 (70)
DHPN + 500 μ g/ml nZnO	10	10 (100)	1.83 ± 1.05	5 (50.0)	0.30 ± 0.31	10 (100)	2.13 ± 1.23	10 (100)
Vehicle	6	0	0	0	0	0	0	0
500 μ g/ml nZnO	6	2 (33.3)	0.16 ± 0.26	0	0	2 (33.3)	0.16 ± 0.26	6 (100)

^a ACH, Ade, EHTB, and Inc. are abbreviations for alveolar cell hyperplasia, adenoma, epithelial hyperplasia of terminal bronchioles, and incidence, respectively

^b Multiplicity is expressed as mean ± s.d

** and *** represent *p* values <0.01 and 0.001, respectively, versus DHPN + vehicle or vehicle

alveolar cell hyperplasia and adenoma in the groups treated with nZnO were not significantly different from the DHPN alone group. In the rats which received nZnO treatment without prior DHPN treatment, alveolar cell proliferation foci, recognized as thickening of the alveolar wall with proliferative alveolar epithelium, were observed, but significant differences from the saline group were not observed. In the mammary gland,

significant inter-group difference in incidence and multiplicity of mammary tumors was also not observed (data not shown).

A notable lesion induced in all the nZnO-treated groups was epithelial hyperplasia of terminal bronchioles (EHTB). The EHTB lesions had increased cell density, often with the epithelial cells arranged in 1–3 layers, and partly extended bronchiolar structures with transition to the normal




Fig. 1 Induction of EHTB by nZnO. **a** representative normal terminal bronchiolar epithelium (NTBE); **b** EHTB in H&E-stained slides; **c** images and localizations of DHPN-induced alveolar hyperplasia

(*arrow*) and nZnO-induced EHTB (*arrow heads*); **d** images of PCNA immunostaining in NTBE; and **e** in EHTB

terminal bronchioles (Fig. 1a, b). The EHTB lesions were independently localized from the DHPN-induced alveolar cell hyperplastic lesions (Fig. 1c). The incidences and multiplicity (number/cm² lung tissue section) of EHTB in the groups treated with nZnO were significantly increased compared with that of the DHPN alone group. The increase was dose-dependent (Spearman rank correlation test, $p < 0.001$) (Table 1). Immunostaining with proliferating cell nuclear antigen (PCNA) indicated that proliferating bronchiolar epithelial cells were preferentially found in the EHTB lesions, but rarely found in the normal terminal bronchial epithelial areas (Fig. 1d, e).

Another lesion found in the groups treated with nZnO, and also independent of DHPN treatment, was interstitial pneumonitis (Fig. 2a). The lesion was usually associated with fibrosis of various thicknesses of the septal wall extruding into the alveolar structure (blue staining in Fig. 2b). Quantitative analysis indicated a significant increase in the fibrotic area in the rats treated with nZnO compared with that of rats treated with DHPN alone (Fig. 2c), and the increase was dose-dependent (Spearman rank correlation test, $p < 0.001$). In addition, the EHTB lesions often occurred near or within interstitial pneumonitis areas.

Light microscopic observation of the alveoli of the rats treated with nZnO showed infiltration of numerous macrophages mixed with a few neutrophils, eosinophils, and lymphocytes (data not shown). The nZnO particles were not found in any of the alveolar macrophages; these macrophages contained numerous vacuolar vesicles in the cytoplasm (Fig. 2d). Transmission electron microscopic (TEM) observation showed that nZnO particles were not found within the vacuolar vesicles (Fig. 2e) or in any alveolar tissue cells (Fig. 2f). The absence of a zinc peak was confirmed by elemental scanning with TEM-X-ray microanalysis (Figure S2). nZnO particles were also not detected under polarized light microscope observation. This feature was in contrast with titanium dioxide nanoparticles which were clearly observed in alveolar macrophages (Figure S3).

Reversibility of EHTB and FAIP in wild-type rats

As in the *Hras128* transgenic rats, nZnO induced EHTB and FAIP in wild-type Sprague–Dawley (SD) rats (Fig. 3a), and nZnO was not found in the lung tissue. nZnO-induced EHTB and FAIP gradually regressed with time (Fig. 3a), and the number of EHTB foci per square centimeter lung tissue section decreased from 9.81 ± 1.42 at day 1 to 0.06 ± 0.13 at week 12 after cessation of nZnO exposure (Fig. 3b). The total Zn²⁺ content in the lung tissue also gradually decreased (Fig. 3c) and was positively correlated with the number of EHTB ($r = 0.96$ by Pearson correlation test).

Microarray analysis

Microarray analysis of the lung tissue indicated that nZnO treatment up-regulated the expression of 738 genes and down-regulated the expression of 267 genes (data not shown). The up-regulated inflammation-associated genes included chemotactic chemokines such as Cxcl5, Cxcl11, Ccl7, Cxcl2, Ccl2, and Cxcl1, proinflammatory cytokines such as Tnfa and Il6, and the acute-phase reactant Orm1 (Table S1). Pathway analysis showed an increase in inflammatory responses in which macrophages and TNF α play a central role (Figure S4). The gene expression profiling was consistent with the strong inflammatory responses in the lung observed by histological examination. Other pathways up-regulated by nZnO included classical complement activation pathway, matrix metalloproteinase pathway, cholesterol biosynthesis pathway and striated muscle contraction pathway, and treatment of nZnO down-regulated the adipogenesis pathway (data not shown).

Effects of ZnCl₂ solution on the lung of wild-type rats

To check whether the nZnO-induced EHTB and FAIP were due to dissolution of nZnO to Zn²⁺, we administered ZnCl₂ solution (the molecular amount is equal to that of 500 μ g/ml nZnO suspension) to the lung of rats by IPS. The lesions were histologically similar to those observed in the nZnO-treated rats (Fig. 4a, b, c). Quantitative analysis of EHTB indicated that the number of EHTB induced by ZnCl₂ solution and nZnO was comparable (Fig. 4d).

To examine whether Zn²⁺ and nZnO have the same underlying molecular mechanisms, two genes, Tnfa and Orm1, which were determined to be up-regulated in the nZnO-treated rats by microarray analysis, were chosen for gene expression analysis. These genes were chosen because Tnfa-encoded tumor necrosis factor alpha is a multifunctional proinflammatory cytokine involved in a variety of acute and chronic inflammatory responses, and Orm1-encoded alpha 1 acid glycoprotein (AGP) is an acute-phase protein usually synthesized by hepatocytes in response to trauma, infection, and inflammation (Fournier et al. 2000). RT-PCR (Fig. 4e) and real-time PCR (Fig. 4f) showed that treatment with both ZnCl₂ solution and nZnO increased the expression of Tnfa and Orm1 genes in the lung tissue, with a little higher induction in the ZnCl₂ solution treated rats. Similarly, increased expression of Orm1 genes was found in primary alveolar macrophages exposed to nZnO in vitro (Fig. 4g). Interestingly, addition of human AGP to nZnO suspension dose-dependently promoted dissolution of nZnO from 59.1 nmol/ml (19.7 % dissolved,




Fig. 2 Induction of FAIP and observation of nZnO particles. **a** representative image of FAIP in rats treated with nZnO; **b** image of Azan–Mallory staining in the lung of rats treated with nZnO, showing collagen fibers; **c** percentage of the fibrotic area in total lung tissue area. *** <0.001 by two-tailed Student's *t*-test versus the

vehicle group; and ### $p < 0.001$ by Spearman rank correlation test. **d** image showing alveolar macrophages with vacuolar phagocytosis vesicles; **e** and **f** TEM images showing alveolar macrophages (*arrow*) and epithelium (*arrow heads*), no nZnO particles being observed

without addition of AGP) to 117.3 nmol/ml (39.1 % dissolved after addition of 500 μg/ml of AGP), while addition of bovine serum albumin (BSA) had little effect on

dissolution of nZnO (Fig. 4h). Exposure of both nZnO and ZnCl₂ solution resulted in dose-dependent cell death in vitro (Figure S5).




Fig. 3 nZnO-induced EHTB and FAIP are reversible. Wild-type rats were treated with 500 $\mu\text{g/ml}$ nZnO by IPS 2 times/week for 4 weeks and killed at different time points of 1 day (1d) and 2, 4, 6, 8, and

12 weeks (wks) after the last IPS. **a** histological images of the lung tissues; **b** number of EHTB per cm^2 lung tissue and **c** Zn^{2+} content in the lung tissues at different time points. Bars = 50 μm

Effects of nZnO particles and ZnCl_2 solution on other organs and serum of wild-type rats

Obvious lesions and macrophages containing vacuolar vesicles were not found in other major organs including

the liver, kidney, spleen, or brain by histological examination (data not shown). The results of blood cell examination are shown in Table S2: The only changes were increased proportions of monocytes and eosinophils that were rapidly recovered within 2 weeks post exposure. Biochemical




Fig. 4 Similar effects of ZnCl₂ solution and nZnO in induction of EHTB and FAIP in wild-type rats. **a** H&E-stained slides of the lungs of rats treated with vehicle; **b** with nZnO; and **c** with ZnCl₂ solution, showing EHTB and FAIP; **d** comparable number of EHTB per square centimeter of the lung tissues induced by treatment of ZnCl₂ and nZnO; **e** gene expression determined by RT-PCR of Orm1 and

Tnfa, with Actb gene as an internal control; **f** real-time PCR analysis of gene expression of Orm1 and Tnfa, which was normalized with Actb expression; **g** induction of Orm1 expression in primary alveolar macrophages exposed to nZnO; and **h** effect of human alpha 1 acid glycoprotein (AGP) and bovine serum albumin (BSA) on dissolution of nZnO in vitro

examination of serum markers for tissue and organ injuries indicated no significant changes compared to the vehicle group (Table S3). Administration of nZnO or ZnCl₂ to the lung led to a transient increase in serum Zn²⁺ concentration which returned to normal levels within 2 weeks after administration. The elevated serum Zn²⁺ did not affect the homeostasis of the other ions examined (Table S4).

Discussion

In vivo nanomaterial toxicity usually implicates oxidative stress, inflammation (Nel et al. 2006), and other biological responses depending on the individual nanomaterial. In vitro assays related to carcinogenicity, such as mammalian cell transformation and gene mutation assays, cannot represent the complex in vivo processes of different biological alterations and are not always suitable for risk assessment of nanomaterial carcinogenicity. In the present study, we tested the carcinogenic activity of nZnO in *Hras128* rats by an initiation–promotion protocol, by which we previously found promotion effect of nanosized titanium dioxide on DHPN-induced lung and mammary carcinogenesis (Xu et al. 2010). nZnO did not show any promotion effects on lung proliferative or neoplastic lesions, indicating that nZnO is not carcinogenic. Also, nZnO did not promote DHPN-induced mammary carcinogenesis.

On the other hand, nZnO was found to induce EHTB in *Hras128* rats and wild-type SD rats. EHTB is a proliferative lesion of the terminal bronchiolar epithelium. It should be noted that the localization of EHTB was independent from that of DHPN-induced alveolar cell hyperplasia. This observation clearly indicates that the DHPN-induced alveolar cell hyperplasia and EHTB have different etiology, the latter being induced by nZnO. We also observed 2 cases of alveolar cell hyperplasia out of 6 cases in the nZnO alone group. This is not significant and thus considered to be spontaneous or an inflammation-associated event. The EHTB lesions regressed when administration of nZnO was discontinued and completely disappeared after 12 weeks. Along with EHTB, the interstitial inflammatory changes often observed surrounding the EHTB lesions also regressed. Our data and other reports (Cho et al. 2011) indicate that the EHTB lesions do not progress directly to cancers but are reactive proliferation associated with inflammatory events. Similar reversible inflammatory changes in the bronchoalveolar lavage fluids by administration of nanoscale or fine ZnO particles via inhalation or intratracheal instillation have previously been reported (Warheit et al. 2009).

nZnO particles were not found in alveolar macrophages, in the lung tissue, or in other organs, suggesting that the

particles were dissolved to Zn²⁺. Accordingly, we conducted experiments to determine whether Zn²⁺ would induce similar lesions. ZnCl₂ solution induced closely similar lung lesions and gene expression profiles as nZnO, demonstrating that the observed lung lesions were caused by Zn²⁺. This was confirmed by increased Zn²⁺ level in the lung and serum after administration of nZnO. Interestingly, treatment with nZnO up-regulated the expression of the *Omr1* gene in both the lung and the alveolar macrophages, and in vitro addition of *Omr1*-encoded AGP dose-dependently promoted nZnO dissolution. After Zn²⁺ was cleared from the lung, the EHTB and FAIP lesions disappeared, and this was evidenced by the positive correlation of EHTB number with Zn²⁺ content in the lung. Dissolution of nZnO has been reported to be particle size- and pH-dependent (Mudunkotuwa et al. 2012). Increased *Omr1* expression possibly alters the microenvironment of the alveolar macrophages and the lung which accelerates nZnO dissolution. The elevated Zn²⁺ from nZnO dissolution possibly interferes with zinc ion homeostasis and leads to cytotoxic effects (Kao et al. 2012).

According to OSHA, the permissible exposure limit for zinc oxide particles is 15 mg/m³ of air for total dust and 5 mg/m³ for the respirable fraction (<http://www.osha.gov/SLTC/healthguidelines/zincoxide/recognition.html>). The inhalation exposure limit per kilogram of body weight per day for the respirable fraction is 192 µg, calculated from 6,000 ml of minute respiratory volume and 8 working hours for a 75 kg body weight worker. The dosing in the carcinogenesis study of the present study was approximately 35.5 and 71 µg/kg body weight a day (calculated from 125 to 250 µg every two weeks for a 250 g rat) and is lower than the OSHA limit for humans. Since nZnO has more potential to be ionized than larger ZnO particles because of its higher surface area (Mudunkotuwa et al. 2012), this feature should be taken into regulatory consideration.

It has been estimated that engineered nanomaterials will become a \$1 trillion enterprise by 2015 (Nel et al. 2006), and ensuring health and environmental safety is a challenging task to the nanotechnology industry. Among numerous engineered nanomaterials, metal based or carbon based, most of which have been shown to have toxic effects to at least some extent, nZnO is a promising nanomaterial for biomedical applications. The results of the present study indicate that, although nZnO induced reversible lung toxicity, it did not cause carcinogenic or chronic progressive inflammatory lesions. Also, since it is biodegradable to ions, nZnO is easily cleared from the body (Rasmussen et al. 2010). Our study also suggests that the toxic effects of nZnO can be further decreased if efforts such as proper dosing and surface coating are made to lower the Zn²⁺ release from nZnO.

In conclusion, treatment of nZnO by IPS did not promote lung and mammary carcinogenesis in our carcinogenesis model. Although nZnO induced EHTB and FAIP, the lesions regressed rapidly along with clearance of surplus Zn²⁺ from the lung and serum. Thus, from a toxicological viewpoint, under the present experimental conditions, exposure of the lung to nZnO does not cause progressive neoplastic development or chronic fibrosis in the lung. These findings will be helpful in evaluating of the safety of nZnO used in biomedical applications, in which its use is of rather short duration, although long-term studies including inhalation studies are required to assess their occupational and environmental health hazards.

Acknowledgments This work was supported by Health and Labor Sciences Research Grants (Research on Risk of Chemical Substance 21340601, H21-kagaku-ippa-008, H24-kagaku-ippa-009 and H22-kagaku-ippa-005) from the Ministry of Health, Labor and Welfare, Japan. We thank A. Iezaki for her excellent secretarial assistance for the work.

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Antonini JM, Lewis AB, Roberts JR, Whaley DA (2003) Pulmonary effects of welding fumes: review of worker and experimental animal studies. *Am J Ind Med* 43:350–360
- Baldwin S, Odio MR, Haines SL, O'Connor RJ, Englehart JS, Lane AT (2001) Skin benefits from continuous topical administration of a zinc oxide/petrolatum formulation by a novel disposable diaper. *J Eur Acad Dermatol Venereol* 15(Suppl 1):5–11
- Cho WS, Duffin R, Howie SE, Scotton CJ, Wallace WA, Macnee W, Bradley M, Megson IL, Donaldson K (2011) Progressive severe lung injury by zinc oxide nanoparticles; the role of Zn²⁺ dissolution inside lysosomes. *Part Fibre Toxicol* 8:27–43
- Deng X, Luan Q, Chen W, Wang Y, Wu M, Zhang H, Jiao Z (2009) Nanosized zinc oxide particles induce neural stem cell apoptosis. *Nanotechnology* 20:115101
- Drinker CK, Fairhall LT (1933) Zinc in relation to general and industrial hygiene. *Public Health Rep* 48:955–961
- Fine JM, Gordon T, Chen LC, Kinney P, Falcone G, Beckett WS (1997) Metal fume fever: characterization of clinical and plasma IL-6 responses in controlled human exposures to zinc oxide fume at and below the threshold limit value. *J Occup Environ Med* 39:722–726
- Fournier T, Medjoubi NN, Porquet D (2000) Alpha-1-acid glycoprotein. *Biochim Biophys Acta* 1482:157–171
- Heinrich U, Fuhst R, Rittinghausen S, Creutzenberg O, Bellmann B, Koch K, Levsen K (1995) Chronic inhalation exposure of wistar rats and two different strains of mice to diesel engine exhaust, carbon black, and titanium dioxide. *Inhalation Toxicol* 7:533–556
- Hughes G, McLean NR (1988) Zinc oxide tape: a useful dressing for the recalcitrant finger-tip and soft-tissue injury. *Arch Emerg Med* 5:223–227
- Hull MJ, Abraham JL (2002) Aluminum welding fume-induced pneumoconiosis. *Hum Pathol* 33:819–825
- Kao YY, Chen YC, Cheng TJ, Chiung YM, Liu PS (2012) Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity. *Toxicol Sci* 125:462–472
- Keramanizadeh A, Gaiser BK, Hutchison GR, Stone V (2012) An in vitro liver model—assessing oxidative stress and genotoxicity following exposure of hepatocytes to a panel of engineered nanomaterials. *Part Fibre Toxicol* 9:28
- Lee J, Kang BS, Hicks B, Chancellor TF Jr, Chu BH, Wang HT, Keselowsky BG, Ren F, Lele TP (2008) The control of cell adhesion and viability by zinc oxide nanorods. *Biomaterials* 29:3743–3749
- Mudunkotuwa IA, Rupasinghe T, Wu CM, Grassian VH (2012) Dissolution of ZnO nanoparticles at circumneutral pH: a study of size effects in the presence and absence of citric acid. *Langmuir* 28:396–403
- Nel A, Xia T, Madler L, Li N (2006) Toxic potential of materials at the nanolevel. *Science* 311:622–627
- Rasmussen JW, Martinez E, Louka P, Wingett DG (2010) Zinc oxide nanoparticles for selective destruction of tumor cells and potential for drug delivery applications. *Expert Opin Drug Deliv* 7:1063–1077
- Sano T (1963) Pathology and pathogenesis of pneumoconiosis. *Acta Pathol Jpn* 13:77–93
- Sayes CM, Reed KL, Warheit DB (2007) Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. *Toxicol Sci* 97:163–180
- Tsuda H, Fukamachi K, Ohshima Y, Ueda S, Matsuoka Y, Hamaguchi T, Ohnishi T, Takasuka N, Naito A (2005) High susceptibility of human c-Ha-ras proto-oncogene transgenic rats to carcinogenesis: a cancer-prone animal model. *Cancer Sci* 96:309–316
- Valdiglesias V, Costa C, Kilic G, Costa S, Pasaro E, Laffon B, Teixeira JP (2013) Neuronal cytotoxicity and genotoxicity induced by zinc oxide nanoparticles. *Environ Int* 55:92–100
- Warheit DB, Sayes CM, Reed KL (2009) Nanoscale and fine zinc oxide particles: can in vitro assays accurately forecast lung hazards following inhalation exposures? *Environ Sci Technol* 43:7939–7945
- Xia T, Kovochich M, Liang M, Madler L, Gilbert B, Shi H, Yeh JJ, Zink JJ, Nel AE (2008) Comparison of the mechanism of toxicity of zinc oxide and cerium oxide nanoparticles based on dissolution and oxidative stress properties. *ACS Nano* 2:2121–2134
- Xu J, Futakuchi M, Iigo M, Fukamachi K, Alexander DB, Shimizu H, Sakai Y, Tamano S, Furukawa F, Uchino T, Tokunaga H, Nishimura T, Hirose A, Kanno J, Tsuda H (2010) Involvement of macrophage inflammatory protein 1 alpha (MIP 1 alpha) in promotion of rat lung and mammary carcinogenic activity of nanoscale titanium dioxide particles administered by intra-pulmonary spraying. *Carcinogenesis* 31:927–935
- Yang H, Liu C, Yang D, Zhang H, Xi Z (2009) Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. *J Appl Toxicol* 29:69–78

LIHIT LAB.

M-289